• Elevated plasma levels of histo–blood group ABO system transferase are associated with increased risk of future venous thromboembolism.

  • The association is only partly explained by plasma levels of von Willebrand factor or coagulation factor VIII.

Abstract

The non-O blood group is a well-established risk factor for venous thromboembolism (VTE). However, the association between plasma levels of the histo–blood group ABO system transferase (BGAT), the gene product of the ABO locus, and VTE risk remains unclear. We aimed to investigate the association between plasma BGAT levels and risk of future VTE, and whether this relationship was mediated by plasma von Willebrand factor (VWF) or coagulation factor VIII (FVIII), as VWF is glycosylated by BGAT. Incident VTE-cases (n = 294) and a randomly sampled age- and-sex-weighted subcohort (n = 1066) were derived from the third survey of the Trøndelag Health Study. Baseline plasma samples (2006-2008) were subjected to the SomaScan aptamer-based-7K platform for protein measurements. Weighted Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) across BGAT quartiles. We found that ABO haplotypes (A1/A2/B/O1/O2) explained ≈80% of the BGAT plasma variability. Participants with BGAT levels in the highest quartile had 2-fold higher VTE risk (HR, 2.12; 95% CI, 1.39-3.22) compared with those with BGAT in the lowest quartile in age-, sex-, and sample batch–adjusted models. The associations were particularly pronounced for unprovoked VTE (HR, 3.71; 95% CI, 1.79-7.67) and deep vein thrombosis (HR, 3.28; 95% CI, 1.63-6.59). The HRs were similar after further adjustment for body mass index, C-reactive protein, and estimated glomerular filtration rate, and moderately attenuated when adding VWF or FVIII plasma levels to the models. Our findings indicate that elevated BGAT plasma levels are associated with increased risk of future VTE beyond what is explained by VWF and FVIII.

1.
Dick
W
,
Schneider
W
,
Brockmueller
K
,
Mayer
W
.
Interrelations of thrombo-embolic diseases and blood-group distribution
.
Thromb Diath Haemorrh
.
1963
;
143
:
472
-
474
.
2.
Jick
H
,
Westerholm
B
,
Vessey
M
, et al
.
Venous thromboembolic disease and ABO blood type: a cooperative study
.
Lancet
.
1969
;
293
(
7594
):
539
-
542
.
3.
Wu
O
,
Bayoumi
N
,
Vickers
MA
,
Clark
P
.
ABO(H) blood groups and vascular disease: a systematic review and meta-analysis
.
J Thromb Haemost
.
2008
;
6
(
1
):
62
-
69
.
4.
Dentali
F
,
Sironi
A
,
Ageno
W
, et al
.
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature
.
Semin Thromb Hemost
.
2012
;
38
(
5
):
535
-
548
.
5.
Yamamoto
F
,
Clausen
H
,
White
T
,
Marken
J
,
Hakomori
S
.
Molecular genetic basis of the histo-blood group ABO system
.
Nature
.
1990
;
345
(
6272
):
229
-
233
.
6.
Ward
SE
,
O'Sullivan
JM
,
O'Donnell
JS
.
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis
.
Blood
.
2020
;
136
(
25
):
2864
-
2874
.
7.
Yamamoto
F
.
Molecular genetics and genomics of the ABO blood group system
.
Ann Blood
.
2021
;
6
:
25
.
8.
Edvardsen
MS
,
Hindberg
K
,
Hansen
ES
, et al
.
Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism
.
Blood Adv
.
2021
;
5
(
1
):
224
-
232
.
9.
Morelli
VM
,
de Visser
MC
,
van Tilburg
NH
, et al
.
ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens
.
Thromb Haemost
.
2007
;
97
(
4
):
534
-
541
.
10.
Lowe
G
,
Wu
O
,
Van Hylckama Vlieg
A
,
Folsom
A
,
Rosendaal
F
,
Woodward
M
.
Plasma levels of coagulation factors VIII and IX and risk of venous thromboembolism: systematic review and meta-analysis
.
Thromb Res
.
2023
;
229
:
31
-
39
.
11.
Morelli
VM
,
De Visser
MCH
,
Vos
HL
,
Bertina
RM
,
Rosendaal
FR
.
ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden
.
J Thromb Haemost
.
2005
;
3
(
1
):
183
-
185
.
12.
Ohira
T
,
Cushman
M
,
Tsai
MY
, et al
.
ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)
.
J Thromb Haemost
.
2007
;
5
(
7
):
1455
-
1461
.
13.
Hansson
K
,
Stenflo
J
.
Post-translational modifications in proteins involved in blood coagulation
.
J Thromb Haemost
.
2005
;
3
(
12
):
2633
-
2648
.
14.
Kano
T
,
Kondo
K
,
Hamako
J
,
Matsushita
F
,
Sakai
K
,
Matsui
T
.
Effects of plasma glycosyltransferase on the ABO(H) blood group antigens of human von Willebrand factor
.
Int J Hematol
.
2018
;
108
(
2
):
139
-
144
.
15.
O’Donnell
J
,
Boulton
FE
,
Manning
RA
,
Laffan
MA
.
Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels
.
Arterioscler Thromb Vasc Biol
.
2002
;
22
(
2
):
335
-
341
.
16.
Ibrahim-Kosta
M
,
Bailly
P
,
Silvy
M
, et al
.
ABO blood group, glycosyltransferase activity and risk of venous thromboembolism
.
Thromb Res
.
2020
;
193
:
31
-
35
.
17.
Brækkan
SK
,
Onsaker
AL
,
Nøst
TH
, et al
.
The plasma proteome and risk of future venous thromboembolism: results from the HUNT study
.
Thromb Haemost
.
2024
.
18.
Åsvold
BO
,
Langhammer
A
,
Rehn
TA
, et al
.
Cohort profile update: the HUNT study, Norway
.
Int J Epidemiol
.
2023
;
52
(
1
):
e80
-
e91
.
19.
Hagen
K
,
Stovner
LJ
,
Nilsen
KB
,
Kristoffersen
ES
,
Winsvold
BS
.
The impact of C-reactive protein levels on headache frequency in the HUNT study 2006-2008
.
BMC Neurol
.
2019
;
19
(
1
):
229
.
20.
Levey
AS
,
Stevens
LA
,
Schmid
CH
, et al
.
A new equation to estimate glomerular filtration rate
.
Ann Intern Med
.
2009
;
150
(
9
):
604
-
612
.
21.
Brumpton
BM
,
Graham
S
,
Surakka
I
, et al
.
The HUNT study: a population-based cohort for genetic research
.
Cell Genom
.
2022
;
2
(
10
):
100193
.
22.
Goumidi
L
,
Thibord
F
,
Wiggins
KL
, et al
.
Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation
.
Blood
.
2021
;
137
(
17
):
2394
-
2402
.
23.
Næss
M
,
Kvaløy
K
,
Sørgjerd
EP
, et al
.
Data resource profile: the HUNT biobank
.
Int J Epidemiol
.
2024
;
53
(
3
):
dyae073
.
24.
Candia
J
,
Daya
GN
,
Tanaka
T
,
Ferrucci
L
,
Walker
KA
.
Assessment of variability in the plasma 7k SomaScan proteomics assay
.
Sci Rep
.
2022
;
12
(
1
):
17147
.
25.
Jones
E
.
cchs: An R package for stratified case-cohort studies (version 0.4.2)
.
R J
.
2018
;
10
(
1
):
484
-
494
.
26.
Clarke
R
,
Shipley
M
,
Lewington
S
, et al
.
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies
.
Am J Epidemiol
.
1999
;
150
(
4
):
341
-
353
.
27.
Lenting
PJ
,
van Mourik
JA
,
Mertens
K
.
The life cycle of coagulation factor VIII in view of its structure and function
.
Blood
.
1998
;
92
(
11
):
3983
-
3996
.
28.
Vasan
SK
,
Rostgaard
K
,
Majeed
A
, et al
.
ABO blood group and risk of thromboembolic and arterial disease
.
Circulation
.
2016
;
133
(
15
):
1449
-
1457
.
29.
Evensen
LH
,
Arnesen
CAL
,
Rosendaal
FR
, et al
.
The risk of venous thromboembolism attributed to established prothrombotic genotypes
.
Thromb Haemost
.
2022
;
122
(
7
):
1221
-
1230
.
30.
Clarke
R
,
Shipley
M
,
Lewington
S
, et al
.
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies
.
Am J Epidemiol
.
1999
;
150
(
4
):
341
-
353
.
31.
Van Langevelde
K
,
Flinterman
LE
,
Van Hylckama Vlieg
A
,
Rosendaal
FR
,
Cannegieter
SC
.
Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum
.
Blood
.
2012
;
120
(
5
):
933
-
946
.
32.
Rietveld
IM
,
Lijfering
WM
,
le Cessie
S
, et al
.
High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor
.
J Thromb Haemost
.
2019
;
17
(
1
):
99
-
109
.
33.
Hansen
E-S
,
Edvardsen
MS
,
Aukrust
P
, et al
.
Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism
.
J Thromb Haemost
.
2023
;
21
(
10
):
2844
-
2853
.
34.
De Visser
MCH
,
Van Hylckama Vlieg
A
,
Tans
G
, et al
.
Determinants of the APTT- and ETP-based APC sensitivity tests
.
J Thromb Haemost
.
2005
;
3
(
7
):
1488
-
1494
.
35.
Gudjonsson
A
,
Gudmundsdottir
V
,
Axelsson
GT
, et al
.
A genome-wide association study of serum proteins reveals shared loci with common diseases
.
Nat Commun
.
2022
;
13
(
1
):
480
.
36.
Lee
HJ
,
Barry
CH
,
Borisova
SN
, et al
.
Structural basis for the inactivity of human blood group O2 glycosyltransferase
.
J Biol Chem
.
2005
;
280
(
1
):
525
-
529
.
37.
Yamamoto
F
,
McNeill
PD
,
Yamamoto
M
,
Hakomori
S
,
Bromilow
IM
,
Duguid
JK
.
Molecular genetic analysis of the ABO blood group system: 4: another type of O allele
.
Vox Sang
.
1993
;
64
(
3
):
175
-
178
.
38.
Smith
JG
,
Gerszten
RE
.
Emerging affinity-based proteomic technologies for large-scale plasma profiling in cardiovascular disease
.
Circulation
.
2017
;
135
(
17
):
1651
-
1664
.
39.
Emilsson
V
,
Ilkov
M
,
Lamb
JR
, et al
.
Co-regulatory networks of human serum proteins link genetics to disease
.
Science
.
2018
;
361
(
6404
):
769
-
773
.
40.
Gold
L
,
Ayers
D
,
Bertino
J
, et al
.
Aptamer-based multiplexed proteomic technology for biomarker discovery
.
PLoS One
.
2010
;
5
(
12
):
e15004
.
41.
Katz
DH
,
Robbins
JM
,
Deng
S
, et al
.
Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer- and antibody-based methods
.
Sci Adv
.
2022
;
8
(
33
):
eabm5164
.
42.
Emilsson
V
,
Gudmundsdottir
V
,
Gudjonsson
A
, et al
.
Coding and regulatory variants are associated with serum protein levels and disease
.
Nat Commun
.
2022
;
13
(
1
):
481
.
43.
Krokstad
S
,
Langhammer
A
,
Hveem
K
, et al
.
Cohort profile: the HUNT study, Norway
.
Int J Epidemiol
.
2013
;
42
(
4
):
968
-
977
.
You do not currently have access to this content.
Sign in via your Institution